AstraZeneca Plc (AZN)

43.87
0.26 0.59
NYSE : Health Technology
Prev Close 44.13
Open 44.18
Day Low/High 43.67 / 44.20
52 Wk Low/High 35.30 / 46.22
Volume 1.65M
Avg Volume 3.45M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 114.91B
EPS 0.80
P/E Ratio 19.79
Div & Yield 1.37 (3.10%)
China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Keep Trading AstraZeneca From the Long Side

Keep Trading AstraZeneca From the Long Side

The stock is headed toward a bullish golden cross.

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Stocks declined on Tuesday as wild weather stifled activity and led to low volume.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Wake Up Wall Street: Donald Trump to Address Congress

Wake Up Wall Street: Donald Trump to Address Congress

U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.

Global Financial News: Nikkei 225 Snaps Losing Streak

Global Financial News: Nikkei 225 Snaps Losing Streak

Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close

AstraZeneca Has Started a Turnaround

AstraZeneca Has Started a Turnaround

The old saying that volume precedes price could be playing out

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

Here is a round-up of the headlines from Europe.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.

AstraZeneca upgraded at Leerink

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.

What to Watch This Week: Presidential Election, Mylan Earnings

What to Watch This Week: Presidential Election, Mylan Earnings

For the week of November 7, all eyes will be on Tuesday's presidential election.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.